Cannabidiol (Epidiolex)

Small molecule

Also known as GWP42003

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy, Lennox-Gastaut Syndrome, Dravet Syndrome, Developmental and Epileptic Encephalopathies

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • Treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older
Product first approved 2018Outside this platform's coverageFDA label
EU
  • Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.
Product first approved 2019EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (16)
Developmental and Epileptic Encephalopathies
NCT04485104 · Jazz Pharmaceuticals
2021-05-19 – 2025-01-28 · Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
What this study did
NCT02224703 · Jazz Pharmaceuticals
2015-04-13 – 2018-04-09 · Epilepsy, Dravet Syndrome
What this study did
Epilepsy
NCT05288283 · Jazz Pharmaceuticals
2022-10-31 – 2023-09-28 · Seizures Associated With EMAS
What this study did
NCT02954887 · Jazz Pharmaceuticals
2017-05-12 – 2019-06-13 · Infantile Spasms
What this study did
NCT02953548 · Jazz Pharmaceuticals
2017-04-24 – 2018-05-07 · Infantile Spasms
What this study did
Lennox-Gastaut Syndrome
Other / comorbidity
NCT07148206 · Montefiore Medical Center
2026-10 – 2028-05 · Opioid Use Disorder
What this study did
NCT07123467 · Wayne State University
2025-11-03 – 2027-08-31 · Generalized Anxiety Disorder (GAD), Anxiety Disorders
What this study did
NCT04252586 · Jazz Pharmaceuticals
2020-02-28 – 2021-06-09 · Rett Syndrome, RTT
What this study did
NCT03848832 · Jazz Pharmaceuticals
2019-07-29 – 2021-01-21 · Rett Syndrome, RTT
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT06333041 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2026-04-01 – 2028-12 · Sanfilippo Syndrome, Mucopolysaccharidosis III
What this study did
NCT04387617 · Mayo Clinic
2021-02-15 – 2022-01-31 · Urinary Stone
What this study did
NCT04423341 · Silkiss Eye Surgery
2020-05-20 – 2021-10-01 · Blepharospasm, Blepharospasm, Benign Essential, CBD
What this study did
Phase 2 (31)
Developmental and Epileptic Encephalopathies
NCT02091206 · Jazz Pharmaceuticals
2014-10-22 – 2015-03-09 · Epilepsy, Dravet Syndrome
What this study did
Epilepsy
NCT02607891 · Jazz Pharmaceuticals
2016-11-09 – 2018-10-02 · Epilepsy
What this study did
NCT02564952 · Jazz Pharmaceuticals
2016-03-11 – 2017-06-07 · Epilepsy
What this study did
NCT02565108 · Jazz Pharmaceuticals
2016-01-20 – 2016-07-21 · Epilepsy
What this study did
Other / comorbidity
NCT07564245 · Assistance Publique - Hôpitaux de Paris
2026-05 – 2030-02 · Neurodevelopmental Disorders With Severe Self-injuries
What this study did
NCT06234631 · Chad Brummett
2024-03-13 – 2029-01 · Knee Replacement Surgery, Osteoarthritis, Knee
What this study did
NCT06213233 · Kevin Boehnke
2024-02-12 – 2028-12 · Pain, Chronic
What this study did
NCT07778810 · Johns Hopkins University
2026-09-17 – 2028-07 · Sturge - Weber Syndrome (SWS)
What this study did
NCT06840899 · University of Wisconsin, Madison
2026-02-13 – 2028-05 · Supra-sacral Spinal Cord Injury, Spinal Cord Injury, Urinary Incontinence
What this study did
NCT06731894 · City of Hope Medical Center
2025-10-03 – 2028-01-07 · Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
What this study did
NCT04992624 · Steven E Harte, PhD
2022-02-22 – 2027-06-30 · Osteoarthritis, Knee, Osteoarthritis of the Knee
What this study did
NCT05066308 · Massachusetts General Hospital
2022-01-04 – 2026-05-01 · Back Pain, Depressive Symptoms
What this study did
NCT04105231 · Lone Baandrup
2021-06-01 – 2026-03-31 · Dual Diagnosis
What this study did
NCT04517799 · University of California, San Diego
2020-06-01 – 2025-12-31 · Autism, Autism Spectrum Disorder
What this study did
NCT04978428 · University of Chicago
2022-04-14 – 2025-11-01 · Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder), Tourette Syndrome, Hoarding Disorder
What this study did
NCT04567784 · Yasmin Hurd
2020-11-12 – 2025-06-18 · Heroin Abuse, Opioid Use Disorder, Substance-Related Disorders, Opioid-Related Disorders
What this study did
NCT05823753 · University of California, San Diego
2023-04-19 – 2024-08-20 · Social Anxiety, Social Anxiety Disorder
What this study did
NCT04745026 · Jazz Pharmaceuticals
2021-05-31 – 2023-12-21 · Autism Spectrum Disorder
What this study did
NCT05651607 · Assistance Publique - Hôpitaux de Paris
2023-09-07 – 2023-11-17 · Hereditary Epidermolysis Bullosa
What this study did
NCT05388058 · Mayo Clinic
2022-06-09 – 2023-07-28 · Chemotherapy-Induced Peripheral Neuropathy, Malignant Solid Neoplasm
What this study did
NCT04447846 · Anne Comi, MD
2019-10-14 – 2022-12-09 · Sturge-Weber Syndrome
What this study did
NCT04982029 · Brigham and Women's Hospital
2022-04-14 – 2022-12-02 · Opioid-use Disorder
What this study did
NCT04192370 · Brigham and Women's Hospital
2020-08-03 – 2021-12-30 · Opioid-use Disorder
What this study did
NCT02818777 · University of Colorado, Denver
2016-10 – 2017-11 · Parkinson's Disease
What this study did
NCT02006628 · Jazz Pharmaceuticals
2014-02-25 – 2015-01-08 · Schizophrenia, Schizophrenia-related Psychotic Disorder
What this study did
NCT01562314 · GW Research Ltd
2012-05-09 – 2014-08-05 · Ulcerative Colitis
What this study did
NCT01491490 · GW Research Ltd
2011-10 – 2012-10 · Schizophrenia
What this study did
NCT01217112 · Jazz Pharmaceuticals
2010-10 – 2012-09 · Dyslipidemias, Diabetes Mellitus, Type 2
What this study did
NCT01284634 · GW Research Ltd
2011-05-03 – 2012-07-13 · Fatty Liver
What this study did
Phase 1/2 (8)
Other / comorbidity
NCT07278505 · Icahn School of Medicine at Mount Sinai
2025-10-29 – 2030-02-28 · Early Life Adversity, Trauma, Stress
What this study did
NCT06381791 · The Methodist Hospital Research Institute
2024-05-24 – 2027-12-30 · Shoulder Osteoarthritis, Rotator Cuff Injuries
What this study did
NCT06930703 · Icahn School of Medicine at Mount Sinai
2025-04-03 – 2027-02-01 · Sickle Cell Disease
What this study did
NCT05132699 · The University of Texas Health Science Center at San Antonio
2022-04-04 – 2023-06-30 · Posttraumatic Stress Disorder, Stress Disorders, Post-Traumatic
What this study did
NCT04642404 · The University of Texas Health Science Center at San Antonio
2021-03-01 – 2023-03-13 · Odontalgia, Toothache
What this study did
NCT04238754 · Johns Hopkins University
2020-11-01 – 2022-06-30 · Opioid Withdrawal, Opioid Craving, Opioid Use Disorder
What this study did
NCT02332655 · Anne Comi, MD
2014-12 – 2021-04 · Sturge-Weber Syndrome
What this study did
NCT03904849 · Medical University of South Carolina
2019-10-01 – 2020-04-30 · Alcohol Use Disorder
What this study did
Phase 1 (18)
Epilepsy
NCT07233239 · Jazz Pharmaceuticals
2025-11-26 – 2027-11-29 · Focal Seizures
What this study did
NCT04721691 · Northwell Health
2021-03-10 – 2024-01-17 · Electrical Status Epilepticus of Slow-Wave Sleep
What this study did
NCT02700412 · University of Alabama at Birmingham
2015-04 – 2019-08-08 · Epilepsy, Seizures
What this study did
NCT02695537 · University of Alabama at Birmingham
2015-04 – 2019-02-27 · Epilepsy, Seizures
What this study did
Other / comorbidity
NCT07001930 · Johns Hopkins University
2025-08-25 – 2029-09-01 · CBD, Stress, Nicotine Dependence, Tobacco Smoking
What this study did
NCT07886606 · Yale University
2021-12-08 – 2027-12-31 · Chronic Pain, Opioid Use Disorder
What this study did
NCT07918469 · Avata Biosciences Holdings Ltd
2026-10-20 – 2027-04-30 · Focal Onset Seizure
What this study did
NCT07462559 · Helsinki University Central Hospital
2026-03-04 – 2026-12-31 · Drug Drug Interaction
What this study did
NCT04878627 · University of California, San Diego
2022-01-20 – 2026-06 · Anorexia Nervosa
What this study did
NCT05672342 · City of Hope Medical Center
2024-07-06 – 2025-10-31 · Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
What this study did
NCT05490511 · Indiana University
2022-10-31 – 2025-08-31 · CBD, Transplant Complication, Kidney Disease, Chronic
What this study did
NCT04587791 · Yale University
2021-12-08 – 2025-03-19 · Chronic Pain, Opioid Use Disorder
What this study did
NCT06192589 · Food and Drug Administration (FDA)
2024-02-08 – 2024-09-06 · Cannabidiol, Drug Induced Liver Injury, Drug Interaction
What this study did
NCT04231643 · University of California, San Diego
2021-09-01 – 2023-11-28 · Bipolar Disorder
What this study did
NCT05269706 · Yasmin Hurd
2022-05-18 – 2023-02-16 · Opioid Use Disorder
What this study did
NCT05023070 · Icahn School of Medicine at Mount Sinai
2021-07-22 – 2023-02-16 · Healthy
What this study did
NCT04428203 · Zin W Myint
2020-08-03 – 2021-08-20 · Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma
What this study did
NCT03102918 · Mclean Hospital
2016-02-20 – 2017-08-30 · Cannabis Use Disorder
What this study did
Phase 4 (11)
Developmental and Epileptic Encephalopathies
NCT06924827 · Elizabeth Donner
2027-01-01 – 2029-06 · Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
What this study did
NCT05044819 · Jazz Pharmaceuticals
2021-07-07 – 2028-03-31 · Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
What this study did
Epilepsy
NCT05324449 · Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
2022-04-05 – 2025-05-05 · Anxiety, Epilepsy
What this study did
NCT04899050 · University of South Florida
2021-07-30 – 2023-05-27 · Study the Efficacy of Epidiolex for Typical Absence Seizures
What this study did
Lennox-Gastaut Syndrome
NCT07728097 · Jazz Pharmaceuticals
2026-11-18 – 2028-12-28 · Lennox-Gastaut Syndrome
What this study did
NCT04133480 · Jazz Pharmaceuticals
2020-10 – 2021-12 · Lennox-Gastaut Syndrome
What this study did
Other / comorbidity
NCT05649059 · Massachusetts Institute of Technology
2025-07-10 – 2027-05 · Phobia, Social
What this study did
NCT05864846 · Jazz Pharmaceuticals
2023-06-29 – 2026-04-06 · Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
What this study did
NCT04749628 · Hospital for Special Surgery, New York
2022-11-02 – 2025-01-08 · Pain, Postoperative, Opioid Use, Knee Osteoarthritis
What this study did
NCT04603391 · University of Florida
2021-02-25 – 2021-12-31 · Drug Interaction
What this study did
NCT03891264 · Massachusetts General Hospital
2019-11-13 – 2020-11-23 · Back Pain, Low
What this study did
Used as active comparator (5)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Other / comorbidity
NCT05942911 · Incannex Healthcare Ltd
2023-11-22 – 2025-10-28 · Rheumatoid Arthritis
What this study did
Phase 1 (4)
Other / comorbidity
NCT07186283 · NW PharmaTech Ltd
2025-09-22 – 2025-12-10 · PK in Healthy Volunteers
What this study did
NCT06578455 · dsm-firmenich Switzerland AG
2024-08-30 – 2024-12-16 · CBD Pharmacokinetics, Healthy Participants
What this study did
NCT04790136 · SocraTec R&D GmbH
2021-03-17 – 2021-05-12 · Comparative Bioavailability
What this study did
NCT02051387 · Central Institute of Mental Health, Mannheim
2013-01 – 2017-08 · Schizophrenia
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 2/3 (1)
Other / comorbidity
NCT04989413 · Hospital Israelita Albert Einstein
2022-10-18 – 2025-02-20 · Chronic Migraine, Headache, Overuse Headache Medication
What this study did
Appears in other studies (204)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (17)
Developmental and Epileptic Encephalopathies
NCT04611438 · Yonsei University
2020-03-30 – 2021-06 · Dravet Syndrome, Lennox Gastaut Syndrome
What this study did
NCT02318563 · INSYS Therapeutics Inc
2017-12-30 – 2018-06-17 · Dravet Syndrome
What this study did
Epilepsy
NCT02783092 · Antonio Waldo Zuardi
2019-01-09 – 2024-09-25 · Epilepsy
What this study did
NCT03421496 · Radius Pharmaceuticals, Inc.
2018-09-05 – 2019-05-29 · Infantile Spasm
What this study did
NCT02318602 · INSYS Therapeutics Inc
2016-01-08 – 2017-06-22 · Seizures
What this study did
Lennox-Gastaut Syndrome
NCT02318537 · INSYS Therapeutics Inc
2017-12-30 – 2018-06-30 · Lennox-Gastaut Syndrome
What this study did
Other / comorbidity
NCT05867849 · University of British Columbia
2023-10-15 – 2030-12 · Bipolar Disorder
What this study did
NCT07245238 · Khon Kaen University
2025-11-05 – 2028-12 · Mediciine, Systemic Sclerosis (SSc), Intervention Study
What this study did
NCT05840822 · Avecho Biotechnology
2024-05-16 – 2027-12 · Insomnia
What this study did
NCT06940674 · Icahn School of Medicine at Mount Sinai
2025-06-13 – 2027-08-15 · Opioid Use Disorder (OUD)
What this study did
NCT06708299 · Cardiol Therapeutics Inc.
2025-04-07 – 2026-10-21 · Recurrent Pericarditis
What this study did
NCT04977986 · Harmony Biosciences Management, Inc.
2021-09-13 – 2025-08-29 · Fragile X Syndrome, Fragile X Syndrome (FXS)
What this study did
NCT06099171 · Humanitas Clinical and Research Center
2024-02-01 – 2025-03-01 · Neck Pain
What this study did
NCT04527003 · Milton S. Hershey Medical Center
2020-12-04 – 2024-06-26 · Endometriosis, CBD, Pelvic Pain
What this study did
NCT04729179 · Marius Henriksen
2021-03-01 – 2024-02-14 · Fibromyalgia
What this study did
NCT03549819 · McMaster University
2021-12-15 – 2024-02 · Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia
What this study did
NCT04271917 · University of Tennessee
2020-02-24 – 2022-03-31 · Pain, Acute
What this study did
Phase 2/3 (13)
Other / comorbidity
NCT07148843 · Johns Hopkins University
2026-10-21 – 2030-10-31 · Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving
What this study did
NCT05020028 · NYU Langone Health
2022-06-22 – 2027-09 · Knee Arthritis
What this study did
NCT05613608 · University of Colorado, Denver
2023-04-30 – 2027-04 · Alcohol Use Disorder
What this study did
NCT03802799 · Zynerba Pharmaceuticals, Inc.
2018-11-09 – 2026-06-30 · Fragile X Syndrome
What this study did
NCT06514066 · Hospital Pengajar Universiti Putra Malaysia
2024-09-01 – 2025-10-01 · Dementia, Vascular, Dementia, Mixed
What this study did
NCT04613102 · Elena Pope
2020-08-01 – 2022-12-30 · Epidermolysis Bullosa, Pain, Itch
What this study did
NCT04615949 · Cardiol Therapeutics Inc.
2021-04-30 – 2022-11-30 · COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
What this study did
NCT05283161 · FG Brasil LTDA
2022-04-15 – 2022-11-20 · Fibromyalgia
What this study did
NCT04467918 · University of Sao Paulo
2020-07-06 – 2021-11-16 · SARS-CoV2
What this study did
NCT04504877 · University of Sao Paulo
2020-06-16 – 2020-12-16 · Covid19, Burn Out, Post Traumatic Stress Disorder
What this study did
NCT03614663 · Zynerba Pharmaceuticals, Inc.
2018-06-12 – 2020-06-14 · Fragile X Syndrome
What this study did
NCT03310593 · Hospital de Clinicas de Porto Alegre
2017-11-01 – 2020-03-24 · Bipolar Disorder, Bipolar Depression, Bipolar Affective Disorder
What this study did
NCT03467620 · University of Illinois at Chicago
2018-07 – 2019-07 · Crohn Disease, Inflammatory Bowel Diseases, Cannabis
What this study did
Phase 2 (83)
Epilepsy
NCT05803434 · Meyer Children's Hospital IRCCS
2024-03-14 – 2026-12-01 · Epilepsy, Rare Diseases
What this study did
NCT06523725 · Dr. Paul Lyons
2024-11-01 – 2025-04-15 · Post-traumatic Epilepsy
What this study did
NCT03355300 · Radius Pharmaceuticals, Inc.
2018-02-20 – 2019-06-28 · Childhood Absence Epilepsy
What this study did
NCT03336242 · Radius Pharmaceuticals, Inc.
2017-12-29 – 2019-05-29 · Childhood Absence Epilepsy
What this study did
NCT02551731 · INSYS Therapeutics Inc
2016-01-27 – 2016-09-06 · Spasms, Infantile
What this study did
Other / comorbidity
NCT07527338 · University of Colorado, Boulder
2026-07-01 – 2031-04-01 · Sleep, Alcohol Misuse
What this study did
NCT07279558 · University of Colorado, Denver
2026-04-21 – 2029-08-31 · Alcohol Use Disorder
What this study did
NCT05822362 · University of Colorado, Denver
2024-01-19 – 2029-04 · Mild Cognitive Impairment
What this study did
NCT05269459 · University of Nebraska
2022-12-01 – 2029-04 · PTSD
What this study did
NCT06107062 · University of Colorado, Boulder
2024-07-26 – 2029-03-31 · Cannabis Use Disorder
What this study did
NCT07549256 · Regionshospital Nordjylland
2026-06-12 – 2029-01 · Metastatic Castration Resistant Prostate Cancer (mCRPC)
What this study did
NCT06845124 · Central Institute of Mental Health, Mannheim
2025-07-22 – 2028-09-30 · Alcohol Addiction, Alcoholism
What this study did
NCT06290063 · University of Colorado, Boulder
2024-05-01 – 2028-08-31 · Sleep, Anxiety, Depression, Pain
What this study did
NCT07624279 · American Society of Pain and Neuroscience, Inc.
2026-06-01 – 2028-07-01 · Persistent Post Traumatic Headache
What this study did
NCT06266611 · University of Colorado, Boulder
2024-09-16 – 2028-06-30 · Sleep, Anxiety, Depression, Pain
What this study did
NCT06569394 · University of Colorado, Denver
2024-12-09 – 2028-06-30 · Cannabis Use Disorder
What this study did
NCT06575751 · University of Colorado, Denver
2024-12-04 – 2028-06-30 · Cannabis Use Disorder
What this study did
NCT07224932 · University of Colorado, Denver
2026-11-01 – 2028-06-01 · Restless Leg Syndrome
What this study did
NCT07638189 · University of Tennessee
2026-07-01 – 2028-03-30 · Osteoarthitis
What this study did
NCT06994520 · Khon Kaen University
2025-05-01 – 2027-12-31 · Chronic Pruritus, Eczema, Nummular Eczema, Atopic Dermatitis, Prurigo Nodularis
What this study did
NCT02926859 · Central Institute of Mental Health, Mannheim
2017-04-08 – 2027-12 · Schizophrenia
What this study did
NCT06448923 · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
2025-06-01 – 2027-06 · Fracture
What this study did
NCT06538389 · City of Hope Medical Center
2024-08-26 – 2027-01-24 · Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Breast Adenocarcinoma, Breast Ductal Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma, Progesterone Receptor-Positive Breast Carcinoma
What this study did
NCT06108349 · University of Virginia
2025-07-01 – 2027-01-01 · Carpal Tunnel Syndrome
What this study did
NCT06218056 · University of California, Los Angeles
2024-10-31 – 2026-12-31 · Tobacco Use Disorder, Tobacco Smoking, Tobacco Dependence
What this study did
NCT06672666 · University of Florida
2025-01-06 – 2026-12-31 · Anxiety, Generalized Anxiety Disorder, Sleep Problems
What this study did
NCT05457465 · Mclean Hospital
2023-06-01 – 2026-12 · Bipolar Disorder
What this study did
NCT06477406 · Mclean Hospital
2024-02-27 – 2026-12 · Endometriosis
What this study did
NCT06629389 · Laboratorio Elea Phoenix S.A.
2024-11-28 – 2026-11 · Parkinson Disease
What this study did
NCT03984565 · Staci Gruber, Ph.D.
2024-06-27 – 2026-11 · Chronic Pain
What this study did
NCT07570472 · KU Leuven
2026-03-19 – 2026-06-07 · Sleep Quality
What this study did
NCT04550377 · NYU Langone Health
2021-05-26 – 2026-06 · Post Traumatic Stress Disorder, Traumatic Brain Injury
What this study did
NCT05860699 · Assistance Publique - Hôpitaux de Paris
2024-04-08 – 2026-05-23 · Severe Alcohol Use Disorder (DSM 5)
What this study did
NCT06533657 · ZYUS Life Sciences Inc.
2025-06-12 – 2026-04-15 · Cancer Pain
What this study did
NCT07840924 · Wageningen University
2024-03-26 – 2026-03-28 · Sleep Quality, Multiple Sclerosis, Insomnia
What this study did
NCT05159830 · Hôpital le Vinatier
2024-10-25 – 2026-02-26 · Alcohol Use Disorder
What this study did
NCT05571592 · NYU Langone Health
2023-01-26 – 2025-12-03 · Social Anxiety Disorder
What this study did
NCT03518801 · VA Office of Research and Development
2019-10-01 – 2025-09-30 · PTSD
What this study did
NCT04821856 · Murdoch Childrens Research Institute
2021-05-11 – 2025-08-19 · Intellectual Disability, Child Behavior Problem
What this study did
NCT05299944 · University of Colorado, Denver
2022-03-08 – 2025-08-19 · Opioid Use Disorder
What this study did
NCT05632627 · University of Colorado, Denver
2023-04-11 – 2025-07-07 · Brain Injuries, Traumatic
What this study did
NCT02548559 · Staci Gruber, Ph.D.
2018-08-14 – 2025-03-13 · Anxiety
What this study did
NCT05753007 · Mclean Hospital
2024-02-15 – 2025-02-11 · Glioblastoma
What this study did
NCT05180240 · Cardiol Therapeutics Inc.
2022-07-28 – 2025-02-04 · Acute Myocarditis
What this study did
NCT04520685 · University of Colorado, Denver
2021-12-15 – 2024-12-31 · Autism Spectrum Disorder
What this study did
NCT07651930 · Medical University of Warsaw
2023-12-18 – 2024-11-17 · Parkinson's Disease (PD)
What this study did
NCT02088060 · Central Institute of Mental Health, Mannheim
2015-12-08 – 2024-09-16 · Schizophrenia
What this study did
NCT05494788 · Cardiol Therapeutics Inc.
2023-01-09 – 2024-09-06 · Recurrent Pericarditis
What this study did
NCT05317546 · Medical University of South Carolina
2022-10-01 – 2024-06-25 · Alcohol Use Disorder
What this study did
NCT05387148 · South West Sydney Local Health District
2022-06 – 2024-06 · Alcohol Use Disorder (AUD)
What this study did
Phase 1/2 (18)
Epilepsy
NCT02324673 · INSYS Therapeutics Inc
2015-04-13 – 2016-05-09 · Seizures
What this study did
Other / comorbidity
NCT06222268 · Leslie Lundahl
2026-09 – 2031-09 · PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis Use
What this study did
NCT06381180 · Wayne State University
2025-09-22 – 2030-12-31 · Post Traumatic Stress Disorder, Cannabis Use, Suicide, Veterans, Marijuana
What this study did
NCT05885542 · Medical University of South Carolina
2023-11-01 – 2028-07-31 · Cannabis Use Disorder
What this study did
NCT06414473 · University of Florida
2024-06-14 – 2026-12-31 · Osteoarthritis, Knee
What this study did
NCT06099379 · Centre hospitalier de l'Université de Montréal (CHUM)
2024-06-27 – 2026-12-31 · Cannabis, THC
What this study did
NCT04726475 · University of Texas at Austin
2022-01 – 2024-01 · Anxiety and Fear
What this study did
NCT04760613 · NYU Langone Health
2022-02-03 – 2023-06-07 · Radiculopathy
What this study did
NCT04731116 · Rabin Medical Center
2021-01-10 – 2022-04-30 · COVID-19
What this study did
NCT03248167 · NYU Langone Health
2019-09-16 – 2022-04-20 · Alcohol Use Disorder, Post Traumatic Stress Disorder
What this study did
NCT03252756 · NYU Langone Health
2019-09-01 – 2022-03-16 · Alcohol Use Disorder
What this study did
NCT05498012 · Palacky University
2020-11-05 – 2022-02-01 · Chronic Periodontitis
What this study did
NCT03607643 · Leaf Vertical Inc.
2019-01-15 – 2020-12-15 · Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
What this study did
NCT03805750 · University of California, San Diego
2019-01-22 – 2020-11-30 · Essential Tremor
What this study did
NCT02751359 · University of California, Los Angeles
2016-07 – 2020-04 · Pain
What this study did
NCT01385124 · Rabin Medical Center
2012-09 – 2015-12 · Graft Versus Host Disease
What this study did
NCT01596075 · Rabin Medical Center
2012-07 – 2015-07 · Graft Versus Host Disease
What this study did
NCT01037322 · Meir Medical Center
2010-01 – 2012-09 · Crohn's Disease, Ulcerative Colitis
What this study did
Phase 1 (44)
Developmental and Epileptic Encephalopathies
NCT03467113 · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
2018-01-19 – 2020-06-24 · Dravet Syndrome, Lennox Gastaut Syndrome
What this study did
Other / comorbidity
NCT07434895 · Hannah Harris
2026-08-05 – 2029-12-01 · Cannabis, Abuse Liability, Experimental Pain in Healthy Human Participants
What this study did
NCT06686914 · West Virginia University
2025-06-30 – 2029-05-01 · Cannabidiol Effects, Driving Performance
What this study did
NCT07167446 · Fox Chase Cancer Center
2025-10-14 – 2028-09-07 · Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to Chemotherapy
What this study did
NCT06692933 · Washington State University
2024-06-20 – 2027-12-31 · Interaction
What this study did
NCT05650697 · University of Oklahoma
2026-09 – 2027-12 · Forehead; Wound
What this study did
NCT05015439 · Johns Hopkins University
2023-04-20 – 2027-12 · Autism Spectrum Disorder
What this study did
NCT05445804 · Johns Hopkins University
2022-11-01 – 2027-02-01 · Tobacco Use, Tobacco Smoking, Tobacco Dependence, Tobacco Use Disorder, Tobacco Use Cessation
What this study did
NCT05283382 · University of Connecticut
2024-10-30 – 2027-02 · Anxiety and Fear
What this study did
NCT06617247 · University of Sao Paulo
2024-12-01 – 2026-12-31 · Burnout Syndrome
What this study did
NCT07027566 · Universidade Federal do Para
2025-07-25 – 2026-07 · Dentin Sensitivity
What this study did
NCT04883255 · University of California, San Diego
2023-05-03 – 2026-06-30 · HIV-1-infection
What this study did
NCT06695195 · Brent DeGeorge
2025-06 – 2026-03 · Upper Extremity Muscle Pain, Upper Extremity Bone Pain, Upper Extremity Pain
What this study did
NCT05934500 · Foundation for Orthopaedic Research and Education
2023-10-15 – 2025-12-30 · Post-operative Pain
What this study did
NCT06574100 · University of Saskatchewan
2024-10-26 – 2025-11 · Pharmacokinetics
What this study did
NCT06854783 · Tiamat Australia Pty Ltd
2025-07-14 – 2025-10-01 · Pharmacokinetics
What this study did
NCT02492074 · Central Institute of Mental Health, Mannheim
2024-12 – 2025-05 · Healthy Volunteers, Modeling Psychosis
What this study did
NCT05742724 · McMaster University
2024-01-11 – 2025-03-01 · Cannabis, Chronic Kidney Diseases, Dialysis
What this study did
NCT03877991 · Hadassah Medical Organization
2024-02-19 – 2025-02-19 · Pain
What this study did
NCT06123702 · Hartford Hospital
2024-04-30 – 2024-12-31 · Social Anxiety Disorder
What this study did
NCT03215940 · University of Utah
2018-02-01 – 2024-12-01 · Chronic Pain, Widespread
What this study did
NCT04044729 · University of Utah
2020-03-16 – 2024-12-01 · Chronic Pain
What this study did
NCT05232123 · Castleton University
2023-07 – 2024-12 · Healthy
What this study did
NCT05240755 · Foundation for Orthopaedic Research and Education
2022-07-01 – 2024-08-20 · Post-operative Pain
What this study did
NCT06137027 · The University of The West Indies
2023-09-21 – 2024-02-29 · Postoperative Nausea and Vomiting
What this study did
NCT04911127 · University of California, Los Angeles
2021-10-05 – 2023-12-31 · Rheumatoid Arthritis, Cannabis
What this study did
NCT05044936 · University of New Mexico
2023-05-15 – 2023-05-15 · Muscle Damage
What this study did
NCT04777643 · Yale University
2022-06-07 – 2023-04-27 · CBD, Neural Responses
What this study did
NCT05002114 · Louisiana State University Health Sciences Center Shreveport
2023-01 – 2023-01 · Musculoskeletal Joint Pain
What this study did
NCT04585841 · University of Copenhagen
2020-12-01 – 2022-11-01 · Lean Body Mass, Cannabis, Cancer, Nausea, Cachexia, Emesis, Appetitive Behavior
What this study did
NCT05346562 · University of Split, School of Medicine
2022-04-08 – 2022-10-05 · Hypertension
What this study did
NCT04349930 · University of New Mexico
2021-01 – 2022-09 · Interstitial Cystitis, Bladder Pain Syndrome
What this study did
NCT03634189 · Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud
2021-03-01 – 2021-12-01 · Heart Failure
What this study did
NCT04731779 · Castleton University
2021-08-30 – 2021-11-29 · Healthy
What this study did
NCT03295903 · University of British Columbia
2018-01-01 – 2021-10-01 · Diet Modification
What this study did
NCT04205682 · South West Sydney Local Health District
2020-01 – 2021-01 · Alcohol Withdrawal, Alcohol Dependence
What this study did
NCT05646459 · University of Nebraska
2020-05-14 – 2020-05-14 · Periodontitis, Adult, Inflammation Gum
What this study did
NCT03164512 · Johns Hopkins University
2018-06-01 – 2020-01-22 · Cannabidiol Pharmacokinetics
What this study did
NCT04193631 · Pure Green
2019-12-07 – 2019-12-09 · Musculoskeletal Pain
What this study did
NCT03471559 · Central Institute of Mental Health, Mannheim
2018-12-10 – 2019-08-29 · Pharmacokinetics, Bioavailability
What this study did
NCT02487381 · Central Institute of Mental Health, Mannheim
2015-04 – 2015-08 · Healthy, Modeling Psychosis
What this study did
NCT01893424 · Hadassah Medical Organization
2013-08 – 2015-01 · Pain
What this study did
NCT01180374 · Yale University
2010-02-01 – 2014-10-06 · Healthy
What this study did
NCT01311778 · Hurd,Yasmin, Ph.D.
2010-02 – 2011-10 · Opiate Addiction
What this study did
Phase 4 (3)
Other / comorbidity
NCT05022186 · Aristotle University Of Thessaloniki
2021-04-01 – 2022-12-20 · Mild Cognitive Impairment
What this study did
NCT04607603 · Medical University of Vienna
2020-10-13 – 2022-03-29 · Osteo Arthritis Knee, Pain, Joint
What this study did
NCT04396730 · Oregon Health and Science University
2020-04-08 – 2022-03-02 · Contraception
What this study did
Early phase / not applicable (26)
Other / comorbidity
NCT07271030 · London Metropolitan University
2026-01-16 – 2027-12 · Well-Being, Psychological, Quality of Life, Sexual Behavior, Sexual Pain Disorder
What this study did
NCT07821840 · Associação Pan-Americana Multidisciplinar de Endocanabinologia
2026-11-01 – 2027-04-01 · Generalized Anxiety Disorder
What this study did
NCT07910292 · Medical University of Silesia
2026-11 – 2027-03-30 · Healthy Aging, Cognition
What this study did
NCT07471347 · King's College London
2026-03 – 2026-12 · Cannabis Intoxication
What this study did
NCT05456113 · Penn State University
2024-12-01 – 2026-10-01 · Effect of Drug
What this study did
NCT07445568 · Universidad del Valle de México, Campus Cuernavaca
2025-09-01 – 2025-11-01 · Older Adults (60 - 85 Years Old), OA Knee
What this study did
NCT05892276 · University of Texas at Austin
2024-08-31 – 2025-08-31 · Posttraumatic Stress Disorder
What this study did
NCT07301658 · i+Med S.Coop.
2023-02-27 – 2024-08-07 · Atopic Dermatitis (AD)
What this study did
NCT05285449 · Christopher Bell
2022-02-09 – 2024-05-31 · Diabetes
What this study did
NCT06364254 · University of Northern Colorado
2023-11-11 – 2024-05-30 · Healthy
What this study did
NCT05774574 · Loughborough University
2023-01-20 – 2024-01-05 · Appetitive Behavior, Adverse Effect, Metabolic Health
What this study did
NCT04831294 · Auburn University
2021-07-15 – 2023-12-31 · CBD, Fear, Inhibition
What this study did
NCT06320327 · Joseph Pastina
2022-08-23 – 2023-04-30 · Muscle Soreness
What this study did
NCT06286839 · NextEvo Inc.
2022-05-12 – 2022-12-14 · Immune System and Related Disorders, Immune System Diseases
What this study did
NCT04881539 · University of Northern Colorado
2021-05-15 – 2022-03-18 · Healthy
What this study did
NCT06105138 · Colorado State University
2021-03-09 – 2022-03-03 · Alcohol Use Disorder
What this study did
NCT04971837 · Colorado State University
2021-05-20 – 2021-12-09 · Metabolism, Liver Function, Pharmacokinetics
What this study did
NCT04851392 · University College, London
2019-03-11 – 2021-06-16 · Cannabis, Cannabis Intoxication, Cannabis Use, Cannabis Dependence, Marijuana, THC, CBD, Adolescent Development
What this study did
NCT02932605 · UMC Utrecht
2017-11-03 – 2020-01-31 · Schizophrenia
What this study did
NCT05170217 · King's College London
2017-11-08 – 2019-06-09 · Cannabis Use
What this study did
NCT03537950 · King's College London
2016-08-22 – 2017-03-01 · Autism Spectrum Disorder
What this study did
NCT02902081 · University of Chicago
2013-02 – 2017-03 · Drug Addiction
What this study did
NCT02112292 · Wageningen University
2014-04 – 2015-04-16 · Sensory Science
What this study did
NCT02291536 · Central Institute of Mental Health, Mannheim
2014-02 – 2014-12 · Healthy Humans
What this study did
NCT02291562 · Central Institute of Mental Health, Mannheim
2014-07 – 2014-12 · Healthy Volunteers
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cannabidiol (Epidiolex): this drugApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication
AV078Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication
Huperzine A (SPN-817)Phase 2Small moleculeAcetylcholinesteraseWeak signal
NCT03156439: Participants were given the experimental treatment twice a day, with the dose increased every two to three days until a maximum daily dose of 2.5 mg was reached. Participants tolerated the treatment well, with mild to moderate, transient and non-dose-limiting adverse events.

Large race: only the 63 furthest-along competitors are listed; 10 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cannabidiol (Epidiolex) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1/2Shoulder Osteoarthritis, Rotator Cuff InjuriesRecruiting
Est. primary completion 2026-12-30 · NCT06381791 · CT.gov ↗
What to watch
Phase 1Drug Drug InteractionNot yet recruiting
Est. primary completion 2026-12-31 · NCT07462559 · CT.gov ↗
What to watch
2027 (9)
February 2027 (1)
Phase 1/2Sickle Cell DiseaseRecruiting
Est. primary completion 2027-02-01 · NCT06930703 · CT.gov ↗
What to watch
March 2027 (2)
Phase 1Focal Onset SeizureNot yet recruiting
Est. primary completion 2027-03-15 · NCT07918469 · CT.gov ↗
What to watch
Phase 2Osteoarthritis, Knee, Osteoarthritis of the KneeRecruiting
Est. primary completion 2027-03-22 · NCT04992624 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2/3Sanfilippo Syndrome, Mucopolysaccharidosis IIIRecruiting
Est. primary completion 2027-04 · NCT06333041 · CT.gov ↗
What to watch
May 2027 (1)
Phase 4Phobia, SocialRecruiting
Est. primary completion 2027-05 · NCT05649059 · CT.gov ↗
What to watch
August 2027 (2)
Phase 4EpilepsyActive not recruiting
Est. primary completion 2027-08-01 · NCT05044819 · CT.gov ↗
What to watch
Phase 3Generalized Anxiety Disorder (GAD), Anxiety DisordersRecruiting
Est. primary completion 2027-08-31 · NCT07123467 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1EpilepsyRecruiting
Est. primary completion 2027-11-29 · NCT07233239 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1Chronic Pain, Opioid Use DisorderRecruiting
Est. primary completion 2027-12-31 · NCT07886606 · CT.gov ↗
What to watch
2028 (7)
January 2028 (2)
Phase 4EpilepsyNot yet recruiting
Est. primary completion 2028-01-01 · NCT06924827 · CT.gov ↗
What to watch
Phase 2Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon CarcinomaRecruiting
Est. primary completion 2028-01-07 · NCT06731894 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Supra-sacral Spinal Cord Injury, Spinal Cord Injury, Urinary IncontinenceRecruiting
Est. primary completion 2028-05 · NCT06840899 · CT.gov ↗
What to watch
Phase 3Opioid Use DisorderNot yet recruiting
Est. primary completion 2028-05 · NCT07148206 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Sturge - Weber Syndrome (SWS)Recruiting
Est. primary completion 2028-07 · NCT07778810 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2Pain, ChronicRecruiting
Est. primary completion 2028-12 · NCT06213233 · CT.gov ↗
What to watch
Phase 4EpilepsyNot yet recruiting
Est. primary completion 2028-12-28 · NCT07728097 · CT.gov ↗
What to watch
2029 (3)
January 2029 (1)
Phase 2Knee Replacement Surgery, Osteoarthritis, KneeRecruiting
Est. primary completion 2029-01 · NCT06234631 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Neurodevelopmental Disorders With Severe Self-injuriesNot yet recruiting
Est. primary completion 2029-05 · NCT07564245 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1CBD, Stress, Nicotine Dependence, Tobacco SmokingRecruiting
Est. primary completion 2029-09-01 · NCT07001930 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
Phase 1/2Early Life Adversity, Trauma, StressRecruiting
Est. primary completion 2030-02-28 · NCT07278505 · CT.gov ↗
What to watch

See the full readout calendar ↗